User login
Commemorating the 20th anniversary of BRCA genetic testing, we are increasingly conscious of the social, economic, and medico-legal impacts of genetic cancer risk on both personal and public health. An ever-growing number of medical societies and expert panels have now charged clinicians with the duty to evaluate and manage their patients’ cancer risk profiles, with particular attention to those individuals carrying genetic mutations that confer elevated cancer susceptibility, a process commonly known as hereditary cancer risk assessment, or HCRA.
Click here to download the PDF.
This article is written for women’s health care clinicians, and will address the current status of hereditary cancer genetic testing, focusing on the evolution of pan-cancer, multigene panel testing in the context of value-based medicine.
Click on the video below to watch Dr. Frieder discuss Hereditary Cancer Testing.
Commemorating the 20th anniversary of BRCA genetic testing, we are increasingly conscious of the social, economic, and medico-legal impacts of genetic cancer risk on both personal and public health. An ever-growing number of medical societies and expert panels have now charged clinicians with the duty to evaluate and manage their patients’ cancer risk profiles, with particular attention to those individuals carrying genetic mutations that confer elevated cancer susceptibility, a process commonly known as hereditary cancer risk assessment, or HCRA.
Click here to download the PDF.
This article is written for women’s health care clinicians, and will address the current status of hereditary cancer genetic testing, focusing on the evolution of pan-cancer, multigene panel testing in the context of value-based medicine.
Click on the video below to watch Dr. Frieder discuss Hereditary Cancer Testing.
Commemorating the 20th anniversary of BRCA genetic testing, we are increasingly conscious of the social, economic, and medico-legal impacts of genetic cancer risk on both personal and public health. An ever-growing number of medical societies and expert panels have now charged clinicians with the duty to evaluate and manage their patients’ cancer risk profiles, with particular attention to those individuals carrying genetic mutations that confer elevated cancer susceptibility, a process commonly known as hereditary cancer risk assessment, or HCRA.
Click here to download the PDF.
This article is written for women’s health care clinicians, and will address the current status of hereditary cancer genetic testing, focusing on the evolution of pan-cancer, multigene panel testing in the context of value-based medicine.
Click on the video below to watch Dr. Frieder discuss Hereditary Cancer Testing.
